PCSK9 Inhibitors
Products Alirocumab was approved in the United States in 2015 as the first agent in the group of PCSK9 inhibitors in the form of a solution for injection (Praluent). Evolocumab (Repatha) followed as the second agent in the EU, also in 2015. Structure and properties PCSK9 inhibitors to date are monoclonal antibodies that must be … PCSK9 Inhibitors